Malaria

Researchers are testing two experimental oral antimalarial drugs, cipargamin and INE963, given alone or in combination, against standard malaria treatment. The trial enrolls people aged 12 and older who have uncomplicated falciparum malaria and weigh between 35 and 90 kilograms. …

This study tested how well the drug primaquine prevents the return of P. vivax malaria in 160 adults. Participants had uncomplicated malaria and normal G6PD levels. The goal was to see if a short treatment could stop relapses, aiming for a complete cure.

This study tested a new way to cure vivax malaria, a type of malaria that can come back. Researchers gave a high daily dose of the drug primaquine for a short time, but only after a quick test to check for a genetic condition (G6PD deficiency) that could cause serious side effect…

This study tests a new malaria vaccine called SUM-101 in 69 healthy children and infants aged 5 months to 5 years in Burkina Faso. The goal is to see if the vaccine is safe and triggers a strong immune response. Participants receive three doses, and some infants also receive a ra…

This study tested an experimental RNA-based vaccine called BNT165e to see if it can prevent malaria. 163 healthy adults who had never had malaria received either the vaccine or a placebo. Researchers measured safety, immune responses, and whether the vaccine protected against a c…

This early-stage trial tests a new malaria vaccine called PfSPZ-LARC2 in up to 22 healthy adults who have never had malaria. The vaccine uses live but genetically weakened malaria parasites that stop developing late in the liver, aiming to trigger a stronger immune response than …

This trial tests an experimental malaria vaccine called RH5.2-VLP, given with an adjuvant (Matrix-M) to boost the immune response. Healthy adults aged 18–45 receive three doses, and some volunteers are later exposed to malaria parasites in a controlled setting to see if the vacci…

This study tested two different malaria vaccines—one targeting the blood stage and one the liver stage—alone and in combination. 107 healthy adults and infants in The Gambia received the vaccines to check safety and immune response. The goal is to see if combining them offers bet…

This study tested two experimental malaria vaccines in 345 healthy Indonesian soldiers deployed to a malaria-endemic region. One vaccine uses weakened malaria parasites, and the other uses live parasites with a preventive drug. The goal was to see if either vaccine could safely p…

This study tested a new malaria vaccine made from genetically weakened parasites that stop growing in the liver and cannot cause blood-stage infection. The goal was to see if it is safe and triggers a strong immune response. The trial involved 75 healthy adults and children in Bu…

This study tested the R21/Matrix-M malaria vaccine in 594 children aged 5 to 36 months in Mali. Researchers checked if the vaccine is safe and triggers an immune response, both when given alone and alongside routine childhood vaccines like measles and yellow fever. The goal is to…

This study tested the RTS,S/AS01E malaria vaccine in nearly 78,000 young children in Sub-Saharan Africa. Researchers checked the vaccine's safety and how well it prevents malaria. The goal was to see if the vaccine can be safely used in routine immunization programs to protect ch…

This Phase 1 trial tested a new malaria vaccine that combines two different vaccine components (Pfs230D1 and R21) with an immune-boosting adjuvant called Matrix-M. The study involved 240 healthy adults aged 18 to 50 in Africa. The main goal was to check the vaccine's safety and h…

This early-stage trial tested a new malaria vaccine called AMA1-DiCo in 66 healthy adults—some in Europe never exposed to malaria, and some in Africa who were. The vaccine was given with one of two adjuvants (GLA-SE or Alhydrogel) to boost immune response. The main goal was to ch…

This early-stage trial tested a vaccine called PRIMVAC, designed to prevent malaria during pregnancy. Researchers gave three different doses to 68 healthy adults in France and Burkina Faso to check safety and immune response. The vaccine targets a protein that helps malaria paras…

This study tested a new vaccine designed to stop the malaria parasite from spreading from people to mosquitoes. 105 healthy adults received three doses of the vaccine over several months. The main goal was to check if the vaccine is safe and triggers an immune response. Participa…

This early-stage trial tested an experimental RNA vaccine called BNT165b1 in 60 healthy adults to see if it is safe and triggers an immune response against malaria. The vaccine uses messenger RNA to teach the body to recognize a key malaria protein. The study was completed and fo…

This study tested a new approach to treat vivax malaria, a type that can hide in the liver and come back. Researchers used a quick test to check for a genetic condition (G6PD deficiency) that can cause dangerous side effects with the standard drug primaquine. Then, they gave a hi…

This trial compares two ways of taking the standard malaria treatment for Plasmodium vivax: one group receives chloroquine and primaquine under direct medical supervision, while the other takes the same medication at home with phone check-ins. The goal is to see if unsupervised t…

This trial tests whether giving children with uncomplicated malaria a triple combination of artemisinin-based drugs works better than the standard two-drug treatment. The goal is to see if using three drugs together can delay the malaria parasite from becoming resistant. Children…

This early-stage trial tested a lab-made antibody called MAM01 in 63 healthy adults who had never had malaria. The goal was to see if it is safe and can prevent malaria infection when people are deliberately exposed to the parasite. The study is complete, but results are not yet …

This study tested a new two-drug combination (KAF156 plus a special form of lumefantrine) in 295 children aged 6 months to 18 years with uncomplicated malaria. The goal was to see if the treatment safely clears the parasite and prevents the infection from coming back. The approac…

This study tested a combination of two anti-malarial drugs, cipargamin and KLU156, in 60 people with uncomplicated Plasmodium falciparum malaria. Participants were at least 12 years old and had a confirmed infection. The main goal was to see if the drugs could clear the malaria p…

This study tested a new intravenous drug called cipargamin in 254 adults and children with severe malaria. The goal was to find a safe and effective dose that quickly clears the malaria parasite, especially in areas where standard treatments are becoming less effective. Researche…

This large study in rural India trained village health workers to diagnose and treat common illnesses like high blood pressure, diarrhea, pneumonia, malaria, asthma, and COPD. Over 72,000 adults aged 16-60 from 80 tribal villages took part. The goal was to reduce deaths by at lea…

This study tested the safety and immune response of the R21/Matrix-M malaria vaccine in 122 African children aged 5-36 months, some living with HIV and some without. The goal was to see if the vaccine is safe and produces an immune response in these children. The trial has been c…

This study tested whether a single dose of two antimalarial drugs, M5717 and pyronaridine, can clear the malaria parasite from the blood and prevent new infections in people who have the parasite but no symptoms. 192 adults and adolescents in malaria-endemic areas took part. The …

This study looked at whether finding and treating low-density malaria infections (infections with very few parasites) in children can improve their health and well-being over time. 600 children in Tanzania, aged 6 months to 10 years, took part. The goal was to see if this approac…

This study tested a new malaria drug called KLU156 in over 1,700 adults and children with uncomplicated malaria. It compared KLU156 to a standard treatment, Coartem, to see if it works as well. Some participants continued taking KLU156 for up to two years to check its safety with…

This study tested a monoclonal antibody called TB31F in 167 adults and children in Mali who are regularly exposed to malaria. The goal was to see if the antibody is safe and can reduce the spread of the malaria parasite from humans to mosquitoes. Participants received either the …

This study tested a new approach to fight malaria: giving malaria medicine to everyone in a community, even if they feel fine. The goal was to remove the malaria parasite from the whole community, making it harder for mosquitoes to spread the disease. Over 3,300 people took part,…

This study tested giving a single dose of the drug tafenoquine to everyone in three villages in Myanmar to see if it could safely stop the spread of P. vivax malaria. Over 1,200 people took part, and researchers tracked side effects and malaria cases for six months. The goal was …

This large Phase 3 trial tested whether combining three antimalarial drugs works better than the standard two-drug treatments for uncomplicated malaria in African children. Over 2,500 children aged 6 months to 12 years received either a triple or standard therapy. The goal was to…

This Phase 2 trial tested an experimental drug called INE963 in 52 adults with uncomplicated Plasmodium falciparum malaria. The main goal was to see how quickly the drug clears malaria parasites from the blood. Researchers also checked the 28-day cure rate. The study is part of a…

This study tested a single injection of an antibody called L9LS in healthy Kenyan children aged 5 months to 10 years. The goal was to see if it safely protects against malaria infection caused by the Plasmodium falciparum parasite. The trial involved 912 children and was complete…

Malaria in pregnancy often causes no symptoms, yet it can lead to anaemia, premature birth, and low birth weight. Standard rapid tests miss many of these quiet infections. Researchers are comparing a new high-sensitivity rapid diagnostic test with conventional tests in 930 pregna…

Malaria in pregnancy can hide in the placenta and harm both mother and baby, yet it often goes undetected. This study enrolls about 1,200 pregnant women in Africa to see whether malaria rapid diagnostic tests, blood smears, and PCR on maternal blood can accurately detect or predi…

Researchers in Senegal are testing a new way to care for children under 15 who come to primary health clinics with fever or diarrhea. The strategy combines rapid tests for malaria, dengue, and strep A with a digital tool that suggests treatment based on symptoms and test results.…

This trial tests whether giving infants a preventive dose of the antimalarial drug sulfadoxine-pyrimethamine during routine health visits can lower their risk of malaria and anemia. Researchers will follow about 2,100 children in Cameroon, comparing those in areas receiving this …

This trial tests whether giving infants in Côte d'Ivoire a preventive dose of an antimalarial drug at routine health visits can lower their risk of malaria and anemia. Researchers will compare outcomes for infants in areas receiving this intervention against those receiving stand…

This study tests the safety of an experimental medicine called L9LS in infants aged 1 to 12 months in Mali. It also looks at how L9LS affects the immune response to a malaria vaccine called R21/Matrix-M. The goal is to find a better way to prevent malaria in young children.

This study tests whether giving school children preventive malaria medicine can reduce infections not only in them but also in younger siblings at home. About 1,000 students in rural Malawi will receive either one of two drug combinations or no preventive treatment. Researchers w…

This study tested whether a single dose of an antibody called L9LS can safely prevent malaria in women of childbearing age in Mali. 279 healthy women and men received either the antibody or a placebo and were monitored for 24 weeks. The goal was to see if the antibody could block…

This study tested a new drug called MAM01 to see if it is safe and could help prevent malaria for at least 4 months. It involved 125 healthy adults and children living in parts of Africa where malaria is common. Researchers gave different doses of MAM01 or a placebo and monitored…

This study tested whether specially built houses (Star Homes) could reduce malaria, respiratory infections, and diarrhea in children under 13 in rural Tanzania. Over 1,100 children lived either in a Star Home or a traditional mud house. The Star Homes have screened windows, solar…

This study tested whether giving antimalarial drugs to everyone in high-risk villages and forest workers could lower malaria cases in Thailand. Over 14,000 people took part. The goal was to see if this approach reduces infections from both Plasmodium falciparum and Plasmodium viv…

This large study tested giving infants up to 6 doses of a malaria preventive medicine alongside their regular vaccinations during the first two years of life. Over 94,000 children in Mozambique, Sierra Leone, and Togo took part. The goal was to see if this approach could reduce m…

This study tested two kinds of long-lasting insecticide-treated bed nets across Uganda to see which better prevents malaria. Over 215,000 people took part, and researchers tracked malaria cases reported at health clinics. The goal is to find the most effective net for nationwide …

This study in Malawi looks at whether giving children the RTS,S malaria vaccine along with special insecticide-treated bednets (PBO nets) can lower malaria infection and spread. About 1,700 children aged 7 months to 10 years took part. The goal is to see how well these two tools …

This large phase 3 trial tested whether combining two malaria drugs (SP and DP) works better than either alone to prevent malaria and improve birth outcomes in pregnant women. Over 2,700 HIV-negative women in Uganda received monthly doses of SP, DP, or both. The study tracked com…

Researchers in Lambaréné, Gabon, want to see if they can safely and reliably infect healthy adult volunteers with malaria using bites from local Anopheles gambiae mosquitoes carrying a local strain of Plasmodium falciparum. The team raises the mosquitoes in the lab, feeds them ma…

This large observational study across multiple African sites tracks pregnant women who use antimalarial drugs, especially in the first trimester. The goal is to assess whether these medications are linked to miscarriage, stillbirth, or major birth defects. By following thousands …

This early-stage trial is testing a new drug called GSK4024484 in 156 healthy adults to see if it is safe and how the body handles it. Researchers will also check if food affects the drug. The goal is to gather safety information before testing it in people with malaria.

This study aims to see if it's safe and possible to give healthy Thai adults a controlled infection of P. vivax malaria through mosquito bites. Six volunteers will be infected and monitored closely. The goal is to develop a reliable model for future research on malaria and immune…

This study looked at whether malaria parasites that are resistant to artemisinin drugs spread more easily after standard treatment. Researchers treated 160 people in Uganda who had malaria with either artemether-lumefantrine or dihydroartemisinin-piperaquine. They then used mosqu…

This completed study looked at how the malaria drug artesunate works in 90 Ugandan children aged 6 months to 14 years with severe malaria. Researchers measured drug levels in the blood and tracked vital signs like temperature and blood pressure to see how the body responds. The g…

This study tests a single injection of a new long-acting malaria drug called MMV371 in 32 healthy adults. The main goal is to check if it is safe and how the body processes it. Participants receive either the drug or a placebo and are monitored for about 12 weeks for side effects…

This study looked at whether the malaria parasite in Ethiopia is becoming resistant to artemisinin, the main drug used to treat it. Researchers tested 277 patients across five sites, checking if parasites were still in the blood three days after treatment and looking for a specif…

This study looked at how often people of all ages in Sabou, Burkina Faso, get malaria. Researchers checked 608 healthy volunteers monthly for a year, taking blood samples and asking about symptoms. They also collected mosquitoes from homes and did feeding experiments to understan…

This study looked at whether a new way to treat Malaria Vivax is practical for healthcare workers in Peru. The plan includes a simple test to check a patient's G6PD enzyme level before giving one of two medicines, tafenoquine or primaquine. Researchers trained healthcare provider…

This completed study looked at how common malaria and worm infections are in pregnant women (18 and older) and children (6-12 months old) in two counties of Liberia. Researchers tested blood samples from over 1,200 participants to measure infection rates. The goal was to gather i…

This completed study of 458 people in Burkina Faso aims to develop a tool that estimates how often malaria parasites switch to a form that can spread to mosquitoes. Researchers will measure certain biomarkers in blood samples from people with and without malaria symptoms. The goa…

This study looked at how people's immune systems react to proteins in mosquito saliva after being bitten. Researchers exposed 147 healthy adults in Thailand to lab-grown mosquitoes that can carry malaria or dengue. The goal was to find markers in the blood that show how much expo…

This completed study in western Kenya looked at how well different malaria drugs work and whether the parasites are becoming resistant. Researchers tested four artemisinin-based combination therapies across 28 health facilities over 28 months, involving 316 people with uncomplica…

This study looked at 100 children in Congo with severe malaria to see if computer models could predict who might die. Researchers used blood tests and other data to build machine-learning algorithms. The goal is to help doctors make faster, better treatment decisions for the sick…

This study tested a new experimental drug called MMV367 in 12 healthy adults. Participants were intentionally infected with a controlled, low-level malaria infection to see how well the drug works and how safe it is. The goal was to measure how the body processes the drug and how…

This completed study from a French hospital looked at long-term after-effects in 56 adults who had severe malaria. Researchers used a questionnaire to check for physical, thinking, and emotional problems one year after diagnosis. The goal is to better understand and track these l…

This study surveyed 222 healthcare workers in Sudan to find out what they know and how they feel about the malaria vaccine. Researchers asked about awareness of the vaccine, its safety, and whether workers would recommend it. The results will help design programs to increase vacc…

This completed study in Cameroon followed 406 adults with and without type 2 diabetes for one year. Researchers tested blood and stool samples at four time points to see if diabetes increases the risk of malaria and other parasitic infections. The goal is to understand how non-co…